Aetna Loses Bid To Re-Enter Pfizer Off-Label MDL

Law360, New York (April 20, 2011, 8:03 PM EDT) -- A Massachusetts judge on Wednesday refused to reconsider Aetna Inc.'s suit accusing Pfizer Inc. of improperly marketing the epilepsy drug Neurontin in violation of racketeering and competition laws.

Judge Patti B. Saris of the U.S. District Court for the District of Massachusetts denied Aetna's motion to alter or amend the court's Jan. 8, 2010, order dismissing both Aetna and Guardian Life Insurance Co. from a long-running multidistrict litigation that alleges Pfizer marketed the epilepsy drug for off-label uses.

Aetna claims in its motion to amend that...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.